Citigroup’s VanEck Biotech ETF BBH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $234K | Buy |
+1,246
| New | +$240K | ﹤0.01% | 3937 |
|
|
2025
Q4 | – | Sell |
-2,650
| Closed | -$439K | – | 6078 |
|
|
2025
Q3 | $439K | Sell |
2,650
-2,832
| -52% | -$462K | ﹤0.01% | 3640 |
|
|
2025
Q2 | $840K | Buy |
+5,482
| New | +$816K | ﹤0.01% | 3290 |
|
|
2023
Q1 | – | Sell |
-51
| Closed | -$8.15K | – | 5497 |
|
|
2022
Q4 | $8.15K | Hold |
51
| – | – | ﹤0.01% | 4909 |
|
|
2022
Q3 | $7K | Hold |
51
| – | – | ﹤0.01% | 5103 |
|
|
2022
Q2 | $7K | Hold |
51
| – | – | ﹤0.01% | 5487 |
|
|
2022
Q1 | $8K | Hold |
51
| – | – | ﹤0.01% | 5628 |
|
|
2021
Q4 | $10K | Hold |
51
| – | – | ﹤0.01% | 5556 |
|
|
2021
Q3 | $10K | Sell |
51
-623
| -92% | -$131K | ﹤0.01% | 5458 |
|
|
2021
Q2 | $136K | Buy |
674
+58
| +9% | +$10.8K | ﹤0.01% | 4402 |
|
|
2021
Q1 | $108K | Sell |
616
-77
| -11% | -$13.9K | ﹤0.01% | 4323 |
|
|
2020
Q4 | $117K | Buy |
693
+4
| +0.6% | +$659 | ﹤0.01% | 5408 |
|
|
2020
Q3 | $112K | Sell |
689
-16
| -2% | -$2.6K | ﹤0.01% | 5032 |
|
|
2020
Q2 | $115K | Sell |
705
-29
| -4% | -$4.41K | ﹤0.01% | 5461 |
|
|
2020
Q1 | $94K | Hold |
734
| – | – | ﹤0.01% | 5386 |
|
|
2019
Q4 | $102K | Sell |
734
-56
| -7% | -$7.36K | ﹤0.01% | 5758 |
|
|
2019
Q3 | $93K | Sell |
790
-336
| -30% | -$41.8K | ﹤0.01% | 5724 |
|
|
2019
Q2 | $146K | Buy |
1,126
+172
| +18% | +$21.2K | ﹤0.01% | 5535 |
|
|
2019
Q1 | $123K | Hold |
954
| – | – | ﹤0.01% | 5551 |
|
|
2018
Q4 | $106K | Hold |
954
| – | – | ﹤0.01% | 5604 |
|
|
2018
Q3 | $130K | Hold |
954
| – | – | ﹤0.01% | 5655 |
|
|
2018
Q2 | $114K | Sell |
954
-40
| -4% | -$4.71K | ﹤0.01% | 5593 |
|
|
2018
Q1 | $120K | Buy |
994
+190
| +24% | +$23.8K | ﹤0.01% | 5435 |
|
|
2017
Q4 | $100K | Hold |
804
| – | – | ﹤0.01% | 5635 |
|
|
2017
Q3 | $108K | Hold |
804
| – | – | ﹤0.01% | 5504 |
|
|
2017
Q2 | $101K | Hold |
804
| – | – | ﹤0.01% | 5331 |
|
|
2017
Q1 | $96K | Sell |
804
-930
| -54% | -$109K | ﹤0.01% | 5239 |
|
|
2016
Q4 | $186K | Buy |
1,734
+930
| +116% | +$101K | ﹤0.01% | 5336 |
|
|
2016
Q3 | $93K | Buy |
804
+80
| +11% | +$9.12K | ﹤0.01% | 5244 |
|
|
2016
Q2 | $74K | Sell |
724
-49,750
| -99% | -$5.31M | ﹤0.01% | 5318 |
|
|
2016
Q1 | $5.23M | Hold |
50,474
| – | – | 0.01% | 1513 |
|
|
2015
Q4 | $6.4M | Buy |
50,474
+1
| +0% | +$123 | 0.01% | 1489 |
|
|
2015
Q3 | $5.77M | Sell |
50,473
-12,540
| -20% | -$1.66M | 0.01% | 1544 |
|
|
2015
Q2 | $8.5M | Buy |
63,013
+12,540
| +25% | +$1.67M | 0.01% | 1321 |
|
|
2015
Q1 | $6.54M | Sell |
50,473
-100
| -0.2% | -$12.6K | 0.01% | 1519 |
|
|
2014
Q4 | $5.83M | Sell |
50,573
-358
| -0.7% | -$40.3K | 0.01% | 1680 |
|
|
2014
Q3 | $5.39M | Sell |
50,931
-1,400
| -3% | -$142K | ﹤0.01% | 1771 |
|
|
2014
Q2 | $4.99M | Sell |
52,331
-50,123
| -49% | -$4.49M | ﹤0.01% | 1797 |
|
|
2014
Q1 | $9.32M | Buy |
102,454
+2,103
| +2% | +$204K | 0.01% | 1206 |
|
|
2013
Q4 | $8.88M | Buy |
100,351
+73
| +0.1% | +$6.11K | 0.01% | 1346 |
|
|
2013
Q3 | $8.3M | Buy |
100,278
+98,393
| +5,220% | +$7.73M | 0.01% | 1329 |
|
|
2013
Q2 | $129K | Buy |
+1,885
| New | +$131K | ﹤0.01% | 4637 |
|
Other funds holding BBH
MIM
CCA
BFG
Citigroup's BBH Position: Q1 2026 in Review
Citigroup opened a new position in VanEck Biotech ETF (BBH) in Q1 2026: 1,246 shares worth $234K. The stake represents ﹤0.01% of the portfolio and ranks #3937 among its holdings. This is a return to the name: Citigroup previously reported a position in BBH as recently as Q3 2025.
Citigroup first reported a position in BBH in Q2 2013 and has held it in 42 quarters since. The position peaked at $9.32M in Q1 2014. 112 funds tracked by Wall St. Rank hold BBH as of Q1 2026.
- Citigroup held 1,246 shares of VanEck Biotech ETF worth $234K as of Q1 2026.
- VanEck Biotech ETF was a new Citigroup position in Q1 2026.
- VanEck Biotech ETF made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #3937 holding.
- Citigroup first reported a position in VanEck Biotech ETF in Q2 2013 and has held it in 42 quarters since.
- Citigroup's VanEck Biotech ETF position peaked at $9.32M in Q1 2014.
- 112 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q1 2026.
Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.